Anhui Fengyuan Pharmaceutical Co., Ltd. canceled the acquisition of Anhui Tiger Biotech Co., Ltd. from Anhui Taige Biological Technology Co., Ltd.
June 19, 2023
Share
Anhui Fengyuan Pharmaceutical Co., Ltd. (SZSE:000153) agreed to acquire Anhui Tiger Biotech Co., Ltd. from Anhui Taige Biological Technology Co., Ltd. on April 7, 2023. Under the terms, consideration will paid in CNY 7.71 per share in cash. Transaction is subject to approval from Anhui Fengyuan's shareholders, board. stock exchange and CRCS. For the period ended 2022, Anhui Tiger Biotech had CNY 392.58 million of total assets, CNY 145.18 million of net assets, CNY 219.94 million of revenue, CNY 35.91 million operating profit and CNY 32.60 million of Net Profit.
Anhui Fengyuan Pharmaceutical Co., Ltd. (SZSE:000153) canceled the acquisition of Anhui Tiger Biotech Co., Ltd. from Anhui Taige Biological Technology Co., Ltd. on June 20, 2023.
ANHUI FENGYUAN PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, manufacture and distribution of biological medicines, chemical synthetic medicines and Chinese medicines. The Company's products mainly include antipyretic and analgesic, women and children, the nervous system, cardiovascular, urinary system, nutrition, antibiotics and active ingredient and other products. The Company is also engaged in the retailing and wholesale of drugs. The Company conducts its businesses mainly in domestic markets, with Anhui province as its main market.